论文部分内容阅读
吡喃阿霉素系1979年日本学者梅泽滨夫等半合成的新蒽环类抗瘤抗生素,系在阿霉素的4’-0位上接上四氢吡喃基而成。本文报告我国三家医院试用吡喃阿霉素联合化疗治疗55例恶性肿瘤,包括非何杰金氏淋巴瘤、小细胞型肺癌、乳癌及头颈部癌;另55例相应肿瘤应用阿霉素联合化疗作对照观察。结果表明,吡喃阿霉素联合化疗与阿霉素联合化疗的疗效(CR率及总缓解率)无差异,吡喃阿霉素引起的脱发比阿霉素明显较少见。吡喃阿霉素引起的Ⅰ度白细胞下降较多,但Ⅲ-Ⅳ度白细胞减少较少见,胃肠道反应无大差别,因观察时间短,两组均未见明显心脏毒性。
Pyrazomycin is a novel anthracycline antitumor antibiotic that was semi-synthesized by a Japanese scholar, M. Metzing, in 1979, and is a tetrahydropyranyl group attached to the 4’-0 position of adriamycin. This article reported that three hospitals in China trialed piramirubin in combination with chemotherapy to treat 55 cases of malignant tumors, including non-Hodgkin’s lymphoma, small cell lung cancer, breast cancer and head and neck cancer; another 55 cases of corresponding tumors using doxorubicin Chemotherapy was used as a control observation. The results showed that there was no difference in the efficacy (CR rate and total remission rate) of pirarubicin combined with chemotherapy and doxorubicin combined chemotherapy, and the hair loss caused by pirarubicin was significantly less than that of doxorubicin. The pirarubicin caused more leukocytopenia in grade I, but less leukocytopenia in grade III-IV, and there was no significant difference in gastrointestinal tract reaction. No obvious cardiotoxicity was observed in both groups because of short observation time.